Back

Patient characteristics and real-world outcomes among atrial fibrillation patients treated with direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in Spain

1 April 2025 (08:00 - 14:15)
Organised by: Logo
Congress Presentation Part of: Poster session 3: clinical management of arrhythmias Oral Anticoagulation EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Rafael Salguero-Bodes

12th of October University Hospital, Madrid (Spain)

139 More presentations in this session

Presentation thumbnail
The relationship between left atrial electroanatomical voltage mapping and CMR-based fibrosis for enhanced preplanning in atrial fibrillation ablation
Doctor Z. Dadon (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Cardiac sympathetic denervation for different cardiovascular indications - the experience of two referral centers
Doctor A. Zienciuk-Krajka (Gdansk, PL)
Abstract
Presentation thumbnail
Practicing physicians perception of feasibility and usefulness of quality indicators of treatment for atrial fibrillation
Doctor J. Simic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Risk of left atrial thrombus in patients undergoing catheter ablation for atrial fibrillation and atrial flutter
Assistant Professor F. Guerra (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Clustering analysis of left atrial smax patterns: predicting atrial fibrillation termination and associations with key clinical factors
Mr J. Huh (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3: clinical management of arrhythmias

The Event

Event poster

EHRA 2025

1 April 2025 08:00 CET
You may be interested in
thumbnail
Congress Presentation
From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Presentation
Anticoagulation strategy of choice for atrial fibrillation ablation - a network meta-analysis of complication rates

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources